Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma Ltd has submitted a quarterly compliance certificate from its Registrar and Transfer Agent, Bigshare Services Pvt. Ltd., under SEBI Regulation 74(5), confirming that all dematerialization requests received during the quarter ending 30 September 2025 were processed and the name of the depository was substituted as the registered owner within the required 15-day timeline. The shareholding pattern shows a sharp rise in total equity shares from 58.9 lakh (as on 30 June 2025) to 143.53 lakh (as on 30 September 2025), with NSDL holdings rising from ~9.47 lakh to ~35.48 lakh and CDSL holdings rising from ~28.39 lakh to ~87.03 lakh, while physical shares stayed nearly flat at ~21 lakh. The filing also notes that the company has received in-principle listing approval from the stock exchanges for the increased 1.43 crore equity shares, suggesting a corporate action such as a bonus or stock split took place in this quarter. Total number of security holders stands at 7,473. One SEBI investor complaint was received during the quarter and has been fully resolved.
This is a routine regulatory compliance filing and is largely procedural, with no direct earnings or business impact. However, retail investors should take note of the substantial increase in total share count (roughly 2.4x), which points to a recent corporate action (likely bonus issue or stock split) that would proportionally adjust the share price and per-share metrics — existing holdings remain unchanged in value but each share now represents a smaller slice of the company.